Academy of Managed Care Pharmacy (AMCP) 2021
Clinical Burden Of Illness Survey Results For U.S. Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving C5 Inhibitors
Improvements In Fatigue And Physical Function Evaluated Through Changes In Clinical Outcomes In Paroxysmal Nocturnal Hemoglobinuria: Post-Hoc Analyses From The Pegasus Study
Model Structure Considerations For Cost-Effectiveness Evaluation Of C3 Inhibitor Pegcetacoplan Vs. C5 Inhibitor In Patients With Paroxysmal Nocturnal Hemoglobinuria
Work Productivity Loss And Quality Of Life In Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors In The United States